Zai Lab Ltd (ZLAB): Cost of Revenue
$190.52M
Year ended 2025-12-31
$195.54M
Trailing 12 months to 2026-06-30
+37.0%
3-year compound annual growth
+62.7%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $190.52M | +29.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $147.12M | +53.5% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $95.82M | +29.4% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $74.02M | +41.7% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $52.24M | +212.1% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $16.74M | +346.4% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $3.75M | n/m | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $43.0K | n/a | 2021-03-01, From 2018-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | 2025-12-31 | $190.52M | +29.5% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $132.42M | +2.1% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $10.34M | +33.5% |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | $20.96M | +440.5% |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | $39.54M | -21.8% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | $124.03M | -11.8% |
| HUTCHMED (China) Ltd (HCM) | 2025-12-31 | $336.35M | -3.6% |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | $36.70M | +91.8% |
| Organogenesis Holdings Inc. (ORGO) | 2024-12-31 | $115.74M | +8.7% |
Compare ZLAB, NATR, TVTX, BBIO side by side · Screen every company in Pharmaceutical Preparations ↗